ClariTrial | Search Clinical Trials

Explore/cardiovascular heart disease

Status

Phase

Pre-filtered to show active, later-stage trials with the strongest clinical signal.

587 results for “cardiovascular heart disease” · Recruiting · Phase 3 · Phase 2

Page 1 of 40

Recruiting

The Effect of phoSPHocreatine on mEdical Emergency Team (Met) tREated Patients

Phase 3HypotensionConsciousness, Level AlteredAirway Disease

PhosphocreatinePlacebo

Università Vita-Salute San Raffaele400 participants1 site · ItalyCompletes Apr 2026

Compare CT.gov Full analysis →

Recruiting

A Study to Evaluate the Efficacy and Safety of BX-001N in Preventing Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI) and Major Adverse Kidney Events (MAKE)

Phase 2Ischemia Reperfusion InjuryCardiac Surgery Associated - Acute Kidney Injury

BX-001N Experimental group 1BX-001N Experimental group 2Placebo

Bilix Co.,Ltd.40 participants5 sites · South KoreaCompletes Jun 2026

Compare CT.gov Full analysis →

Recruiting

Targeting Endoplasmic Reticulum Stress in Human Hypertension

Phase 1Phase 2Hypertension

TUDCAPlacebo

University of North Texas Health Science Center70 participants1 site · United StatesCompletes Dec 2028

Compare CT.gov Full analysis →

Recruiting

Safety and Efficacy of Meplazumab in Patients With Coronary Artery Disease

Phase 2Coronary Artery Disease

Mepolizumab low dose groupMepolizumab middle dose groupMepolizumab high dose group+1 more

Xijing Hospital18 participants1 site · ChinaCompletes Sep 2026

Compare CT.gov Full analysis →

Recruiting

Focused Orticumab Research for Treating Inflammation in Coronary Arteries

Phase 2Acute Coronary SyndromesCoronary Arterial Disease (CAD)Inflammation

OrticumabPlacebo

Abcentra240 participants41 sites · United States, Czechia, HungaryCompletes Feb 2027

Compare CT.gov Full analysis →

Recruiting

[64Cu]FBP8 PET for Early Detection of Intracardiac Thrombus in Amyloid Cardiomyopathy

Phase 3Cardiac Amyloidosis

[64Cu]FBP8 PET/MR

Brigham and Women's Hospital20 participants1 site · United StatesCompletes Mar 2027

Compare CT.gov Full analysis →

Recruiting

Tailored Exercise Training Study Among Adults With HFpEF

Phase 2Phase 3HFpEF - Heart Failure With Preserved Ejection FractionDiabetic Cardiomyopathies

Moderate-intensity continuous training (MCT)Resistance trainingWeight loss

University of Texas Southwestern Medical Center120 participants1 site · United StatesCompletes Dec 2026

Compare CT.gov Full analysis →

Recruiting

Exogenous KETOne Supplements in Patients Hospitalized for Acute Heart Failure

Phase 2Acute Heart Failure (AHF)

1,3-butanediolPlacebo

Aarhus University Hospital250 participants8 sites · DenmarkCompletes Nov 2027

Compare CT.gov Full analysis →

Recruiting

Combined THC and CBD for OUD and Chronic Pain

Phase 2Chronic PainOpioid Use Disorder

CBD 300mgCBD 600mgPlacebo 0mg

Yale University147 participants1 site · United StatesCompletes Jan 2028

Compare CT.gov Full analysis →

Recruiting

Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT

Phase 2MicrotiaDysbiosisAlcohol Drinking

ProbioticPlacebo

Vanderbilt University Medical Center250 participants1 site · United StatesCompletes Aug 2026

Compare CT.gov Full analysis →

Recruiting

Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm in Patients With Acute Respiratory Infection Caused by SARS-Cov-2, Influenza A, Influenza B and Respiratory Syncytial Virus (RSV)

Phase 1Phase 2SARS-CoV-2Influenza, HumanRespiratory Syncytial Virus Infections

Placebo comparatorPRS CK STORMPRS CK STORM

PEACHES BIOTECH50 participants3 sites · SpainCompletes Oct 2026

Compare CT.gov Full analysis →

Recruiting

Stroke Prophylaxis With Apixaban in Chronic Kidney Disease Stage 5 Patients With Atrial Fibrillation

Phase 3Chronic Kidney DiseasesAtrial FibrillationStroke

Apixaban 2.5 milligram Oral Tablet

Region Stockholm1,400 participants34 sites · Finland, Iceland, NorwayCompletes Dec 2027

Compare CT.gov Full analysis →

Recruiting

Comparison of Landiolol Versus Standard of Care for Prevention of Mortality in Patients Hospitalized for a Septic Shock With Hypercontractility

Phase 3Septic ShockTachycardiaMortality During Septic Shock

echocardiographyLandiolol

Centre Hospitalier Universitaire, Amiens360 participants1 site · FranceCompletes Jun 2027

Compare CT.gov Full analysis →

Recruiting

Beta-blOckers discoNtinuation in Patients Presenting Heart FaIlure With REcovered Left Ventricular Ejection Fraction

Phase 3Heart Failure

Βeta-Blockers discontinued (with tapering)

Assistance Publique - Hôpitaux de Paris1,300 participants1 site · FranceCompletes Oct 2027

Compare CT.gov Full analysis →

Recruiting

Nesiritide in Hypertension

Phase 1Phase 2Hypertension

NesiritidePlacebo

Oslo University Hospital15 participants3 sites · NorwayCompletes Dec 2018

Compare CT.gov Full analysis →

1–15 of 587

Explore/cardiovascular heart disease

Status

Phase

Pre-filtered to show active, later-stage trials with the strongest clinical signal.

587 results for “cardiovascular heart disease” · Recruiting · Phase 3 · Phase 2

Page 1 of 40

Recruiting

The Effect of phoSPHocreatine on mEdical Emergency Team (Met) tREated Patients

Phase 3HypotensionConsciousness, Level AlteredAirway Disease

PhosphocreatinePlacebo

Università Vita-Salute San Raffaele400 participants1 site · ItalyCompletes Apr 2026

Compare CT.gov Full analysis →

Recruiting

A Study to Evaluate the Efficacy and Safety of BX-001N in Preventing Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI) and Major Adverse Kidney Events (MAKE)

Phase 2Ischemia Reperfusion InjuryCardiac Surgery Associated - Acute Kidney Injury

BX-001N Experimental group 1BX-001N Experimental group 2Placebo

Bilix Co.,Ltd.40 participants5 sites · South KoreaCompletes Jun 2026

Compare CT.gov Full analysis →

Recruiting

Targeting Endoplasmic Reticulum Stress in Human Hypertension

Phase 1Phase 2Hypertension

TUDCAPlacebo

University of North Texas Health Science Center70 participants1 site · United StatesCompletes Dec 2028

Compare CT.gov Full analysis →

Recruiting

Safety and Efficacy of Meplazumab in Patients With Coronary Artery Disease

Phase 2Coronary Artery Disease

Mepolizumab low dose groupMepolizumab middle dose groupMepolizumab high dose group+1 more

Xijing Hospital18 participants1 site · ChinaCompletes Sep 2026

Compare CT.gov Full analysis →

Recruiting

Focused Orticumab Research for Treating Inflammation in Coronary Arteries

Phase 2Acute Coronary SyndromesCoronary Arterial Disease (CAD)Inflammation

OrticumabPlacebo

Abcentra240 participants41 sites · United States, Czechia, HungaryCompletes Feb 2027

Compare CT.gov Full analysis →

Recruiting

[64Cu]FBP8 PET for Early Detection of Intracardiac Thrombus in Amyloid Cardiomyopathy

Phase 3Cardiac Amyloidosis

[64Cu]FBP8 PET/MR

Brigham and Women's Hospital20 participants1 site · United StatesCompletes Mar 2027

Compare CT.gov Full analysis →

Recruiting

Tailored Exercise Training Study Among Adults With HFpEF

Phase 2Phase 3HFpEF - Heart Failure With Preserved Ejection FractionDiabetic Cardiomyopathies

Moderate-intensity continuous training (MCT)Resistance trainingWeight loss

University of Texas Southwestern Medical Center120 participants1 site · United StatesCompletes Dec 2026

Compare CT.gov Full analysis →

Recruiting

Exogenous KETOne Supplements in Patients Hospitalized for Acute Heart Failure

Phase 2Acute Heart Failure (AHF)

1,3-butanediolPlacebo

Aarhus University Hospital250 participants8 sites · DenmarkCompletes Nov 2027

Compare CT.gov Full analysis →

Recruiting

Combined THC and CBD for OUD and Chronic Pain

Phase 2Chronic PainOpioid Use Disorder

CBD 300mgCBD 600mgPlacebo 0mg

Yale University147 participants1 site · United StatesCompletes Jan 2028

Compare CT.gov Full analysis →

Recruiting

Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT

Phase 2MicrotiaDysbiosisAlcohol Drinking

ProbioticPlacebo

Vanderbilt University Medical Center250 participants1 site · United StatesCompletes Aug 2026

Compare CT.gov Full analysis →

Recruiting

Phase 1Phase 2SARS-CoV-2Influenza, HumanRespiratory Syncytial Virus Infections

Placebo comparatorPRS CK STORMPRS CK STORM

PEACHES BIOTECH50 participants3 sites · SpainCompletes Oct 2026

Compare CT.gov Full analysis →

Recruiting

Stroke Prophylaxis With Apixaban in Chronic Kidney Disease Stage 5 Patients With Atrial Fibrillation

Phase 3Chronic Kidney DiseasesAtrial FibrillationStroke

Apixaban 2.5 milligram Oral Tablet

Region Stockholm1,400 participants34 sites · Finland, Iceland, NorwayCompletes Dec 2027

Compare CT.gov Full analysis →

Recruiting

Comparison of Landiolol Versus Standard of Care for Prevention of Mortality in Patients Hospitalized for a Septic Shock With Hypercontractility

Phase 3Septic ShockTachycardiaMortality During Septic Shock

echocardiographyLandiolol

Centre Hospitalier Universitaire, Amiens360 participants1 site · FranceCompletes Jun 2027

Compare CT.gov Full analysis →

Recruiting

Beta-blOckers discoNtinuation in Patients Presenting Heart FaIlure With REcovered Left Ventricular Ejection Fraction

Phase 3Heart Failure

Βeta-Blockers discontinued (with tapering)

Assistance Publique - Hôpitaux de Paris1,300 participants1 site · FranceCompletes Oct 2027

Compare CT.gov Full analysis →

Recruiting

Nesiritide in Hypertension

Phase 1Phase 2Hypertension

NesiritidePlacebo

Oslo University Hospital15 participants3 sites · NorwayCompletes Dec 2018

Compare CT.gov Full analysis →

1–15 of 587